356 related articles for article (PubMed ID: 34279440)
1. Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products.
Iksen ; Pothongsrisit S; Pongrakhananon V
Molecules; 2021 Jul; 26(13):. PubMed ID: 34279440
[TBL] [Abstract][Full Text] [Related]
2. Exploiting new strategies in combating head and neck carcinoma: A comprehensive review on phytochemical approaches passing through PI3K/Akt/mTOR signaling pathway.
Iranpanah A; Majnooni MB; Biganeh H; Amirian R; Rastegari-Pouyani M; Filosa R; Cheang WS; Fakhri S; Khan H
Phytother Res; 2024 May; ():. PubMed ID: 38776136
[TBL] [Abstract][Full Text] [Related]
3. Natural products and derivatives in renal, urothelial and testicular cancers: Targeting signaling pathways and therapeutic potential.
Li D; Wang J; Tuo Z; Yoo KH; Yu Q; Miyamoto A; Zhang C; Ye X; Wei W; Wu R; Feng D
Phytomedicine; 2024 May; 127():155503. PubMed ID: 38490077
[TBL] [Abstract][Full Text] [Related]
4. Correction: Targeting EGFR/PI3K/AKT/mTOR signaling in lung and colon cancers: synthesis, antitumor evaluation of new 1,2,4-oxdiazoles tethered 1,2,3-triazoles.
Ayoup MS; Shawki I; Abdel-Hamid H; Ghareeb DA; Masoud A; Harras MF; El-Atawy M; Alharbi NS; Ismail MMF
RSC Adv; 2024 May; 14(25):17945. PubMed ID: 38841391
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer.
Li H; Prever L; Hirsch E; Gulluni F
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298731
[TBL] [Abstract][Full Text] [Related]
6. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
Mardanshahi A; Gharibkandi NA; Vaseghi S; Abedi SM; Molavipordanjani S
Mol Biol Rep; 2021 Aug; 48(8):1-14. PubMed ID: 34357550
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.
Huang J; Chen L; Wu J; Ai D; Zhang JQ; Chen TG; Wang L
J Med Chem; 2022 Dec; 65(24):16033-16061. PubMed ID: 36503229
[TBL] [Abstract][Full Text] [Related]
8. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic and molecular differences of anticancer agents on 2D and 3D cell culture.
Alwahsh M; Al-Doridee A; Jasim S; Awwad O; Hergenröder R; Hamadneh L
Mol Biol Rep; 2024 Jun; 51(1):721. PubMed ID: 38829450
[TBL] [Abstract][Full Text] [Related]
10. Identifying the Multitarget Pharmacological Mechanism of Action of Genistein on Lung Cancer by Integrating Network Pharmacology and Molecular Dynamic Simulation.
Das R; Woo J
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731403
[TBL] [Abstract][Full Text] [Related]
11. Identifying lncRNAs and mRNAs related to survival of NSCLC based on bioinformatic analysis and machine learning.
Yue W; Wang J; Lin B; Fu Y
Aging (Albany NY); 2024 May; 16(9):7799-7817. PubMed ID: 38696317
[TBL] [Abstract][Full Text] [Related]
12. Shrimp Lipids Inhibit Migration, Epithelial-Mesenchymal Transition, and Cancer Stem Cells via Akt/mTOR/c-Myc Pathway Suppression.
Thepthanee C; Ei ZZ; Benjakul S; Zou H; Petsri K; Innets B; Chanvorachote P
Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672078
[TBL] [Abstract][Full Text] [Related]
13. Qingfei mixture modulates the immune responses in lung cancer through modulating mTOR signaling and gut microbiota-derived short-chain fatty acids.
Qian X; Chen Z; Ji XM; Ji YL; Wang J; Liu YC; Zhou XC; Li QL; Li CY; Zhang AQ
Heliyon; 2024 Apr; 10(8):e29404. PubMed ID: 38660245
[TBL] [Abstract][Full Text] [Related]
14. Plumbagin induces ferroptosis in colon cancer cells by regulating p53-related SLC7A11 expression.
Wang B; Kong W; Lv L; Wang Z
Heliyon; 2024 Apr; 10(7):e28364. PubMed ID: 38596137
[TBL] [Abstract][Full Text] [Related]
15. Novel 2-Aminobenzothiazole Derivatives: Docking, Synthesis, and Biological Evaluation as Anticancer Agents.
Salih OM; Al-Sha'er MA; Basheer HA
ACS Omega; 2024 Mar; 9(12):13928-13950. PubMed ID: 38559989
[TBL] [Abstract][Full Text] [Related]
16. KRT80 Promotes Lung Adenocarcinoma Progression and Serves as a Substrate for VCP.
Huang S; Tong W; Yang B; Ma L; Zhang J; Wang C; Xu L; Mei J
J Cancer; 2024; 15(8):2229-2244. PubMed ID: 38495507
[No Abstract] [Full Text] [Related]
17. Cardenolide glycosides sensitize gefitinib-induced apoptosis in non-small cell lung cancer: inhibition of Na
Du CM; Leu WJ; Jiang YH; Chan SH; Chen IS; Chang HS; Hsu LC; Hsu JL; Guh JH
Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; ():. PubMed ID: 38451282
[TBL] [Abstract][Full Text] [Related]
18. Rictor-A Mediator of Progression and Metastasis in Lung Cancer.
Szalai F; Sztankovics D; Krencz I; Moldvai D; Pápay J; Sebestyén A; Khoor A
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339294
[TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer.
Morgos DT; Stefani C; Miricescu D; Greabu M; Stanciu S; Nica S; Stanescu-Spinu II; Balan DG; Balcangiu-Stroescu AE; Coculescu EC; Georgescu DE; Nica RI
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339127
[TBL] [Abstract][Full Text] [Related]
20.
Attia HG; El-Morshedy SM; Nagy AM; Ibrahim AM; Aleraky M; Abdelrahman SS; Osman SM; Alasmari SM; El Raey MA; Abdelhameed MF
Metabolites; 2024 Jan; 14(1):. PubMed ID: 38276303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
